Literature DB >> 10861420

Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation.

S N Goldberg1, G S Gazelle, C C Compton, P R Mueller, K K Tanabe.   

Abstract

BACKGROUND: Radiofrequency (RF)-induced tissue coagulation represents a new approach for the thermal destruction of tumors within the liver. The purpose of the current study was to 1) assess technique safety; 2) determine the extent and evolution of induced cellular damage; and 3) correlate the observed pathologic effects with radiologic studies.
METHODS: Twenty-three tumors measuring </= 8 cm (19 colorectal metastases and 4 hepatomas) in 22 patients were treated with RF (range, 500-1550 milliamperes) using internally cooled electrodes. All treated tumors were resected to allow pathologic analysis. Eleven tumors were treated intraoperatively under ultrasonographic guidance and excised immediately. Twelve tumors were treated percutaneously using ultrasound or computed tomography (CT) guidance and subsequently were excised 3-7 days after ablation. Contrast-enhanced CT (n = 12) and magnetic resonance imaging (MRI) (n = 2) were performed after ablation of all percutaneously treated patients.
RESULTS: Tumors treated intraoperatively did not demonstrate definitive coagulative necrosis. However, pathologic abnormalities suggestive of tissue injury were observed with hematoxylin and eosin staining, and absent cytosolic and mitochondrial enzyme activity suggested irreversible cellular damage. In contrast, specimens removed > 3 days after ablation showed definite, contiguous coagulative necrosis without intervening areas of viable tumor. CT and MRI scans demonstrated circumscribed hypodense, nonenhancing regions surrounding the electrode tract as early as 15 minutes after ablation. These corresponded within 2 mm to measurements of coagulation at pathology.
CONCLUSIONS: RF ablation is a minimally invasive and safe approach to the treatment of tumors in the liver. Tumors treated with RF energy do not immediately demonstrate coagulative necrosis, but do show evidence of irreversible cellular damage. The extent of tumor necrosis correlates closely with findings at contrast-enhanced imaging. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Year:  2000        PMID: 10861420

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  102 in total

1.  MR monitoring of tumour thermal therapy.

Authors:  D Germain; P Chevallier; A Laurent; H Saint-Jalmes
Journal:  MAGMA       Date:  2001-08       Impact factor: 2.310

Review 2.  Ablative therapy for liver tumours.

Authors:  E A Dick; S D Taylor-Robinson; H C Thomas; W M W Gedroyc
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

3.  Percutaneous radiofrequency ablation of chordoma.

Authors:  Ziv Neeman; Jay W Patti; Bradford J Wood
Journal:  AJR Am J Roentgenol       Date:  2002-11       Impact factor: 3.959

4.  Quantifying local stiffness variations in radiofrequency ablations with dynamic indentation.

Authors:  Ryan J DeWall; Tomy Varghese; Christopher L Brace
Journal:  IEEE Trans Biomed Eng       Date:  2011-12-08       Impact factor: 4.538

Review 5.  Principles of and advances in percutaneous ablation.

Authors:  Muneeb Ahmed; Christopher L Brace; Fred T Lee; S Nahum Goldberg
Journal:  Radiology       Date:  2011-02       Impact factor: 11.105

Review 6.  The role and limitations of radiofrequency ablation in treatment of bone and soft tissue tumors.

Authors:  Kamran Ahrar
Journal:  Curr Oncol Rep       Date:  2004-07       Impact factor: 5.075

7.  Guidance and control of percutaneous treatments with contrast-enhanced ultrasound.

Authors:  L Solbiati; T Ierace; M Tonolini; L Cova
Journal:  Eur Radiol       Date:  2003-11       Impact factor: 5.315

8.  Recurrence and treatment pattern in long-term survivors with hepatocellular carcinoma: a comparison between radiofrequency ablation and surgery as a first-line treatment.

Authors:  Hyojin Kim; Hyunchul Rhim; Dongil Choi; Hyo K Lim; Young-Sun Kim; Won Jae Lee; Jae Won Joh
Journal:  World J Surg       Date:  2010-08       Impact factor: 3.352

9.  Thermal ablation for unresectable liver tumours, time to move forward?

Authors:  Gianpiero Gravante
Journal:  World J Gastrointest Surg       Date:  2010-01-27

10.  [Regression and therapy-resistance of primary liver tumors and liver metastases after regional chemotherapy and local tumor ablation].

Authors:  H-P Fischer
Journal:  Pathologe       Date:  2005-05       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.